SML0636

SR1664

≥98% (HPLC)

• 別名: 4′-[[2,3-Dimethyl-5-[[[(1S)-1-(4-nitrophenyl)ethyl]amino]carbonyl]-1H-indol-1-yl]methyl]- [1,1′-Biphenyl]-2-carboxylic acid
• 実験式（ヒル表記法）: C₃₃H₂₉N₃O₅
• CAS番号: 1338259-05-4
• 分子量: 547.60
• UNSPSCコード: 12352200
• NACRES: NA.77

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• フォーム: powder
• 保管条件: protect from light
• 色: white to beige
• 溶解性: DMSO: 15 mg/mL, clear
• 保管温度: −20°C
• SMILES記法: [N+](=O)([O-])c1ccc(cc1)[C@@H](NC(=O)c2cc3c([n](c(c3C)C)Cc4ccc(cc4)c5c(cccc5)C(=O)O)cc2)C
• InChI: 1S/C33H29N3O5/c1-20-22(3)35(19-23-8-10-25(11-9-23)28-6-4-5-7-29(28)33(38)39)31-17-14-26(18-30(20)31)32(37)34-21(2)24-12-15-27(16-13-24)36(40)41/h4-18,21H,19H2,1-3H3,(H,34,37)(H,38,39)/t21-/m0/s1
• InChI Key: IIJDFXNUWZTHIM-NRFANRHFSA-N

詳細

生物化学的／生理学的作用

SR1664 is a non-agonist PPARγ ligand and an inhibitor of Cdk5-mediated PPARγ phosphorylation. It has strong antidiabetic activity in two murine models of diabetes without the side effects normally asociated with the thiazolidinedione (TZD) antidiabetic PPARγ agonists. The TZD antidiabetics such as rosiglitazone and pioglitazone are full PPARγ agonists, but recent data have suggested that their separate activity, inhibition of the the obesity-linked PPARγ phosphorylation by Cdk5, is likely the more important activity for antidiabetic action. SR1664 has an IC₅₀ of 80 nM in a competitive binding assay, blocked the Cdk5-mediated phosphorylation of PPARγ in vitro with IC₅₀ between 20 and 200 nM and exhibited no PPARγ agonist activity.

SR1664 is a non-agonist PPARγ ligand and an inhibitor of Cdk5-mediated PPARγ phosphorylation; antidiabetic.

特徴および利点

This compound is featured on the CDKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

その他情報

Light sensitive

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable